MX2023013664A - Inhibidor de mutante de idh y uso del mismo. - Google Patents
Inhibidor de mutante de idh y uso del mismo.Info
- Publication number
- MX2023013664A MX2023013664A MX2023013664A MX2023013664A MX2023013664A MX 2023013664 A MX2023013664 A MX 2023013664A MX 2023013664 A MX2023013664 A MX 2023013664A MX 2023013664 A MX2023013664 A MX 2023013664A MX 2023013664 A MX2023013664 A MX 2023013664A
- Authority
- MX
- Mexico
- Prior art keywords
- idh mutant
- class
- general formula
- present
- mutant inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110661394 | 2021-06-15 | ||
| PCT/CN2022/099018 WO2022262784A1 (zh) | 2021-06-15 | 2022-06-15 | Idh突变体抑制剂及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013664A true MX2023013664A (es) | 2024-01-08 |
Family
ID=84526875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013664A MX2023013664A (es) | 2021-06-15 | 2022-06-15 | Inhibidor de mutante de idh y uso del mismo. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240208978A1 (enExample) |
| EP (1) | EP4356914A4 (enExample) |
| JP (1) | JP7884019B2 (enExample) |
| KR (1) | KR20240021774A (enExample) |
| CN (1) | CN117460512A (enExample) |
| AU (1) | AU2022294860A1 (enExample) |
| BR (1) | BR112023024454A2 (enExample) |
| CA (1) | CA3217608A1 (enExample) |
| MX (1) | MX2023013664A (enExample) |
| WO (1) | WO2022262784A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026035776A1 (en) * | 2024-08-05 | 2026-02-12 | Frontier Medicines Corporation | Pi3k-alpha binding compounds and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012184205A (ja) * | 2011-03-08 | 2012-09-27 | Dainippon Sumitomo Pharma Co Ltd | ２−アミノ置換８−オキソジヒドロプリン誘導体 |
| SMT202200255T1 (it) * | 2012-09-28 | 2022-07-21 | Takeda Pharmaceuticals Co | Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea |
| CA2903979A1 (en) * | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| MA46064B1 (fr) * | 2014-09-19 | 2020-04-30 | Forma Therapeutics Inc | Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase |
| US9624175B2 (en) * | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| WO2017019429A1 (en) | 2015-07-27 | 2017-02-02 | Eli Lilly And Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors |
| JP6682043B2 (ja) | 2016-06-06 | 2020-04-15 | イーライ リリー アンド カンパニー | 変異体ｉｄｈ１阻害剤 |
| CN107556366B (zh) * | 2016-06-30 | 2025-02-07 | 上海海和药物研究开发股份有限公司 | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 |
| KR102232614B1 (ko) * | 2016-07-21 | 2021-03-29 | 난징 산홈 팔마세우티칼 컴퍼니 리미티드 | 이소시트레이트 탈수소효소 억제제의 화학적 화합물 및 이의 적용 |
| JP6793836B2 (ja) * | 2016-12-16 | 2020-12-02 | イーライ リリー アンド カンパニー | 変異体ｉｄｈ１およびｉｄｈ２阻害剤としての７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物 |
| CN110872297B (zh) * | 2018-09-04 | 2023-02-14 | 上海再极医药科技有限公司 | 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用 |
| WO2020141439A1 (en) * | 2018-12-31 | 2020-07-09 | Integral Biosciences Private Limited | Heterocyclic compounds as mutant idh inhibitors |
-
2022
- 2022-06-15 BR BR112023024454A patent/BR112023024454A2/pt unknown
- 2022-06-15 MX MX2023013664A patent/MX2023013664A/es unknown
- 2022-06-15 WO PCT/CN2022/099018 patent/WO2022262784A1/zh not_active Ceased
- 2022-06-15 EP EP22824259.0A patent/EP4356914A4/en active Pending
- 2022-06-15 CN CN202280040684.0A patent/CN117460512A/zh active Pending
- 2022-06-15 US US18/287,885 patent/US20240208978A1/en active Pending
- 2022-06-15 KR KR1020237041032A patent/KR20240021774A/ko active Pending
- 2022-06-15 CA CA3217608A patent/CA3217608A1/en active Pending
- 2022-06-15 JP JP2023577688A patent/JP7884019B2/ja active Active
- 2022-06-15 AU AU2022294860A patent/AU2022294860A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4356914A1 (en) | 2024-04-24 |
| CA3217608A1 (en) | 2022-12-22 |
| BR112023024454A2 (pt) | 2024-02-06 |
| AU2022294860A1 (en) | 2024-01-25 |
| KR20240021774A (ko) | 2024-02-19 |
| EP4356914A4 (en) | 2025-01-08 |
| US20240208978A1 (en) | 2024-06-27 |
| JP7884019B2 (ja) | 2026-07-02 |
| JP2024524933A (ja) | 2024-07-09 |
| WO2022262784A1 (zh) | 2022-12-22 |
| CN117460512A (zh) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022004686A2 (es) | Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo | |
| MX2021010242A (es) | Compuesto inhibidor de jak y uso del mismo. | |
| CR20220281A (es) | Derivados de pirazolilo útiles como agentes anti-cancerígenos | |
| BR112022008717A2 (pt) | Composto de fórmula, um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável ou éster deste, inibidor de aurora quinase, composição farmacêutica, e uso do composto | |
| MX2022001421A (es) | Compuesto tetracíclico, método de preparación y uso del mismo. | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| PY1932509A (es) | Inhibidores de cinasa dependientes de ciclina | |
| MX2019008698A (es) | Derivado de piridina como inhibidor de ask1 y metodo de preparacion y uso del mismo. | |
| CO2022008171A2 (es) | Derivado tricíclico de dihidroimidazopirimidona, método de preparación del mismo, composición farmacéutica y uso del mismo | |
| CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
| MX2020013116A (es) | Sales y cristales novedosos. | |
| CL2022001741A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
| UY32490A (es) | Inhibidores de beta-secretasa | |
| MX2021011144A (es) | Derivados de las benzodiazepinas como inhibidores del vsr. | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| MX2023006751A (es) | Nuevo derivado de camptotecina, composicion que comprende el mismo y su uso. | |
| MX2022005732A (es) | Derivado de amida y metodo de preparacion para el mismo y uso del mismo en medicina. | |
| CO2021000932A2 (es) | Forma cristalina de compuesto profármaco de lanosterol y aplicación de la misma | |
| CR20170003A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
| MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
| CO2021013166A2 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| CL2024002623A1 (es) | Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2. | |
| MX2019012967A (es) | Cristal de base libre de derivados benzofurano y metodo de preparacion. |